Treatment with 1-alpha,25-dihydroxyvitamin D3 (vitamin D 3) to inhibit carcinogenesis in the hamster buccal pouch model

Archives of Otolaryngology - Head and Neck Surgery

Volumn 133, Issue 11, 2007, Pages 1149-1152

  Meier, Jeremy D ^a   Enepekides, Danny J ^a   Poirier, Brian ^a   Bradley, Christopher A ^a   Albala, Joanna S ^a   Farwell, D Gregory ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; DIMETHYLBENZ[A]ANTHRACENE; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MODEL; CARCINOGENESIS; CHEEK POUCH; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HAMSTER; MALE; MOUTH CANCER; NONHUMAN; OUTCOME ASSESSMENT;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CALCITRIOL; CARCINOMA, SQUAMOUS CELL; CHEEK; CRICETINAE; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; INJECTIONS, INTRAPERITONEAL; MALE; MESOCRICETUS; MOUTH NEOPLASMS; VITAMINS;

EID: 36349009705     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archotol.133.11.1149     Document Type: Article

References (21)

1. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc. 1976;35(6):1332-1338.
2. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med. 1993;328(3):184-194.
3. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med. 1990;323(12):795-801.
4. Lin R, White JH. The pleiotropic actions of vitamin D. Bioessays. 2004;26(1):21-28.
5. Fleet JC. Rapid, membrane-initiated actions of 1,25 dihydroxyvitamin D: what are they and what do they mean? J Nutr. 2004;134(12):3215-3218.
6. Rachez C, Freedman LP. Mechanisms of gene regulation by vitamin D(3) receptor: a network of coactivator interactions. Gene. 2000;246(1-2):9-21.
7. Shklar G. Experimental oral pathology in the Syrian hamster. Prog Exp Tumor Res. 1972;16:518-538.
8. Gimenez-Conti I. The hamster cheek pouch carcinogenesis model. Acta Odontol Latinoam. 1993;7(1):3-11.
9. Salley JJ. Experimental carcinogenesis in the cheek pouch of the Syrian hamster. J Dent Res. 1954;33(2):253-262.
10. Santis H, Shklar G. Initiation and promotion in experimental oral carcinogenesis. Oral Surg Oral Med Oral Pathol. 1964;17:84-95.
11. Shklar G. Oral mucosal carcinogenesis in hamsters: inhibition by vitamin E. J Natl Cancer Inst. 1982;68(5):791-797.
12. Schwartz LH, Ozsahin M, Zhang GN, et al. Synchronous and metachronous head and neck carcinomas. Cancer. 1994;74(7):1933-1938.
13. Rubin D, Levij IS. Suppression by vitamins D2 and D3 of hamster cheek pouch carcinoma induced with 9,10-dimethyl-1,2-benzanthracene with a discussion of the role of intracellular calcium in the development of tumors. Pathol Microbiol (Basel). 1973;39(6):446-460.
14. Banach-Petrosky W, Ouyang X, Gao H, et al. Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1; Pten mutant mice. Clin Cancer Res. 2006;12(19):5895-5901.
15. Belleli A, Shany S, Levy J, Guberman R, Lamprecht SA. A protective role of 1,25-dihydroxyvitamin D3 in chemically induced rat colon carcinogenesis. Carcinogenesis. 1992;13(12):2293-2298.
16. Mokady E, Schwartz B, Shany S, Lamprecht SA. A protective role of dietary vitamin D3 in rat colon carcinogenesis. Nutr Cancer. 2000;38(1):65-73.
17. Prudencio J, Akutsu N, Benlimame N, et al. Action of low calcemic 1alpha-25-dihydroxyvitamin D3 analogue EB1089 in head and neck squamous cell carcinoma. J Natl Cancer Inst. 2001;93(10):745-753.
18. McElwain MC, Modzelewski RA, Yu W, Russell DM, Johnson CS, Vitamin D. An antiproliferative agent with potential for therapy of squamous cell carcinoma. Am J Otolaryngol. 1997;18(5):293-298.
19. Muindi JR, Peng Y, Potter DM, et al. Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther. 2002;72(6):648-659.
20. Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL. A phase I trial of calcitriol (1,25-dihydroxyvitamin D3) in patients with advanced malignancy. Clin Cancer Res. 1999;5(6):1339-1345.
21. Beer TM, Munar M, Henner WB. A phase I trial of pulse calcitriol in patients with refractory malignancies. Cancer. 2001;91(12):2431-2439.